Orchard Therapeutics plc - ADR

NASDAQ:ORTX   3:59:51 PM EDT
2.79
-0.06 (-2.10%)
Products, Strategic Combinations

Orchard Therapeutics, Pharming Group Announce Collaboration To Develop And Commercialize Ex Vivo Autologous HSC Gene Therapy For Hereditary Angioedema

Published: 07/01/2021 05:13 GMT
Orchard Therapeutics plc - ADR (ORTX) - Orchard Therapeutics, Pharming Group Announce Collaboration to Develop and Commercialize Ex Vivo Autologous Hsc Gene Therapy for Hereditary Angioedema.
Co Will Receive $17.5 Million Comprising $10 Million in Cash and a $7.5 Million Equity Investment From Pharming.
Eligible to Receive Up to $189.5 Million in Development, Regulatory,sales Milestones & Mid-single to Low Double-digit Royalty Payments on Sales.
Pharming Has Been Granted Worldwide Rights to Otl-105 and Will Be Responsible for Clinical Development, Regulatory Filings, Commercialization.